

---

## Scandion Oncology Q4 2023 - Striving towards randomised controlled data

Redeye comments on Scandion Oncology's Q4 2023 report, with the company having recently presented its plan to drive SCO-101 towards a randomised controlled phase IIb trial in mCRC. We judge the company's strategy as prudent, though it will need to address financing while running some CORIST part 3 extension cohorts in 2024e to prepare for phase IIb. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Scandion Oncology Q4 2023 - Striving towards randomised controlled data](#)